ClinicalTrials.gg
CompletedNCT03677141Updated Dec 18, 2024Results posted

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of Mosunetuzumab and Polatuzumab Vedotin in B-cell Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche. Completed at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell — 5 open to participants now, 8 under way, none of them phase 3. polatuzumab vedotin · Lymphoma, B-Cell.

Enrollment
2nd of 11
117 · median 40
Started
2019
the only one that year
Phase 1/2
2 of 11
1 open now
Registered
2nd of 11
by date
Lead sponsor
2 of 11
Hoffmann-La Roche

Among the 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, and was the 2nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

5 of the 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About polatuzumab vedotin

polatuzumab vedotin: first FDA approval 2019 (POLIVY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).

03

Conditions studied

  • B-cell Non-Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Phase Ib and Phase II Portions

  • At least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest diameter
  • Performance Status of 0, 1, or 2
  • Adequate hematologic function

Inclusion Criteria for Phase Ib Portion

Participants must also meet the following criteria for study entry into the Phase Ib portion:

  • confirmed B-cell NHL according to the World Health Organization (WHO) 2016 classification expected to express the cluster of differentiation-20 (CD20) antigen
  • (R/R) B-cell NHL after at least one prior systemic lymphoma therapy
  • Treatment with at least one prior CD20-directed therapy
  • Group B only: no prior treatment with polatuzumab vedotin

Inclusion Criteria for Phase II Portion

Participants must also meet the following criteria for study entry in the Phase II portion:

  • Previously untreated, histologically confirmed DLBCL according to WHO 2016 classification
  • International Prognostic Index (IPI) score of 2-5

Exclusion Criteria

  • Prior treatment with mosunetuzumab
  • Prior allogenic stem-cell transplant
  • Current Grade >1 peripheral neuropathy
  • Participants with history of confirmed progressive multifocal leukoencephalopathy (PML)
  • Known or suspected chronic active Epstein Barr virus (CAEBV), , (HCV), or (HIV)
  • Prior solid organ transplantation
  • History of disease
  • Current or past history of central nervous system (CNS) lymphoma
  • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
  • Significant cardiovascular disease or pulmonary disease
  • history of liver disease
  • Recent major surgery within 4 weeks before the start of C1D1, other than superficial lymph node for diagnosis

Exclusion Criteria for Phase Ib Portion

Participants who also meet any of the following criteria will be excluded from study entry in the Phase Ib portion:

  • Prior treatment with chemotherapy, immunotherapy, and biologic therapy 4 weeks prior to C1D1
  • Prior treatment with radiotherapy within 2 weeks prior to C1D1
  • Adverse events from prior anti-cancer therapy resolved to ≤Grade 1 (with the exception of alopecia and anorexia)
  • Prior treatment with >250 mg/m\^2 doxorubicin (or equivalent anthracycline dose)

Exclusion Criteria for Phase II Portion

Participants who also meet any of the following criteria will be excluded from study entry in the Phase II portion:

  • Participants with transformed lymphoma
  • Prior therapy for B-cell NHL
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding

    Participants will receive M-CHOP up to the phase II recommended dose (RP2D).

    Drug: Mosunetuzumab · Drug: Polatuzumab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Tocilizumab

  • Experimental
    Phase Ib: M-CHP-Pola Dose-Finding

    Participants will receive M-CHP-Pola up to the RP2D.

    Drug: Mosunetuzumab · Drug: Polatuzumab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: Tocilizumab

  • Experimental
    Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort

    Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.

    Drug: Mosunetuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Tocilizumab

  • Experimental
    Phase II: M-CHP-Pola 1L DLBCL

    Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.

    Drug: Mosunetuzumab · Drug: Polatuzumab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: Tocilizumab

  • Active comparator
    Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL

    Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.

    Drug: Polatuzumab Vedotin · Drug: Rituxumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone

  • Experimental
    Phase II: M-CHOP 1L DLBCL

    Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage. NOTE: No participants were enrolled to this arm.

    Drug: Mosunetuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Tocilizumab

Interventions

  • Participants will receive intravenous (IV) mosunetuzumab.

  • Participants will receive polatuzumab vedotin via IV.

  • Participants will receive rituxumab via IV.

  • Participants will receive cyclophosphamide via IV.

  • Participants will receive doxorubicin via IV.

  • Participants will receive vincristine via IV.

  • Participants will receive oral prednisone.

  • Participants will receive tocilizumab via IV.

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)

    The CR rate was defined as the percentage of participants with CR. Assessments were made according to the Lugano 2014 Response Criteria.

    Time frame: 6-8 weeks after either C6D1 or last dose of study treatment

Secondary outcomes

  1. CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II)

    Time frame: 6-8 weeks after C6D1 or last dose of study treatment

  2. Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II)

    ORR is defined as a CR or PR at the time of primary assessment based on PET-CT, as determined by the investigator.

    Time frame: 6-8 weeks after C6D1 or last dose of study treatment

  3. ORR at PRA Based on CT Only as Determined by the Investigator (Phase II)

    ORR is defined as a CR or PR at the time of primary assessment based on CT only, as determined by the investigator.

    Time frame: 6-8 weeks after C6D1 or last dose of study treatment

  4. Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II)

    Best ORR was defined as CR or PR at any time on study and based on PET-CT or CT only as determined by the investigator.

    Time frame: Up to approximately 50 months

  5. Duration of Response (DOR) as Determined by the Investigator (Phase II)

    DOR is defined as the time from the first occurrence of a documented objective response to disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).

    Time frame: Up to approximately 50 months

  6. Progression-free Survival (PFS) as Determined by the Investigator (Phase II)

    PFS is defined as the time from randomization to the first occurrence of disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The earliest contributing event to PFS is reported. The range (min-max) values are based on censored observations (participants without a baseline-evaluable tumor assessment were censored at the date of randomization or first study treatment, plus 1 day).

    Time frame: Up to approximately 50 months

  7. PFS at 1 Year as Determined by the Investigator (Phase II)

    PFS at 1 year is defined as the proportion of participants with disease progression or relapse as determined by the investigator, or death from any cause within 1 year of randomization.

    Time frame: 1 year

  8. Event-free Survival (EFS) as Determined by the Investigator (Phase II)

    EFS is defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, initiation of new anti-lymphoma therapy (NALT), or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).

    Time frame: Up to 50 months

  9. Time to Deterioration in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale

    Time frame: C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)

  10. Time to Deterioration in Physical Functioning and Fatigue as Measured by the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30)

    Time frame: C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)

  11. Polatuzumab Vedotin Serum Concentrations

    Time frame: C2D1, C6D1

  12. Polatuzumab Vedotin Antibody-conjugated Monomethyl Auristatin E (acMMAE) Serum Concentrations

    Time frame: C1D1-C6D1

  13. Polatuzumab Vedotin Unconjugated Mono-methyl Auristatin E (MMAE) Serum Concentrations

    Time frame: C1D1-C6D1

  14. Mosunetuzumab Serum Concentrations

    Time frame: C1D1-C5D1

  15. Baseline Prevalence and Incidence of Treatment Emergent Anti-drug Antibodies (ADA) to Mosunetuzumab

    Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).

    Time frame: Cycles 1, 2, 6, 16, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)

  16. Baseline Prevalence and Incidence of Treatment Emergent ADA to Polatuzumab Vedotin

    Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).

    Time frame: Cycles 1, 2, 6, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)

07

Results

Posted Dec 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneGroup A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Started348404022
Completed131283119
Not completed2171293
Withdrew: Death216953
Withdrew: Lost to follow-up000200
Withdrew: Screen failure or enrolled in error000020
Withdrew: Physician decision000010
Withdrew: Withdrawal by subject001110

Outcome measures

PrimaryComplete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)

The CR rate was defined as the percentage of participants with CR. Assessments were made according to the Lugano 2014 Response Criteria.

Time frame:
6-8 weeks after either C6D1 or last dose of study treatment
Reported as:
Number · Percentage of participants
Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)
Percentage of participantsArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)72.5 (56.11 to 85.40)77.3 (54.63 to 92.18)
Statistical analysis
  • Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) vs Arm 2: Phase II Rituximab + CHP-Pola (Randomized) · Difference in rates: -4.77 · 95% CI -30.61 to 21.07
SecondaryCR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II)
Time frame:
6-8 weeks after C6D1 or last dose of study treatment
Reported as:
Number · Percentage of participants
CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II)
Percentage of participantsGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II)50.0 (33.80 to 66.20)47.5 (31.51 to 63.87)31.8 (13.86 to 54.87)
SecondaryOverall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II)

ORR is defined as a CR or PR at the time of primary assessment based on PET-CT, as determined by the investigator.

Time frame:
6-8 weeks after C6D1 or last dose of study treatment
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II)
Percentage of participantsGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II)87.5 (73.20 to 95.81)80.0 (64.35 to 90.95)77.3 (54.63 to 92.18)
SecondaryORR at PRA Based on CT Only as Determined by the Investigator (Phase II)

ORR is defined as a CR or PR at the time of primary assessment based on CT only, as determined by the investigator.

Time frame:
6-8 weeks after C6D1 or last dose of study treatment
Reported as:
Number · Percentage of participants
ORR at PRA Based on CT Only as Determined by the Investigator (Phase II)
Percentage of participantsGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
ORR at PRA Based on CT Only as Determined by the Investigator (Phase II)85.0 (70.16 to 94.29)72.5 (56.11 to 85.40)81.8 (59.72 to 94.81)
SecondaryBest ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II)

Best ORR was defined as CR or PR at any time on study and based on PET-CT or CT only as determined by the investigator.

Time frame:
Up to approximately 50 months
Reported as:
Number · Percentage of responders
Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II)
Percentage of respondersGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II)95.0 (83.08 to 99.39)85.0 (70.16 to 94.29)95.5 (77.16 to 99.88)
SecondaryDuration of Response (DOR) as Determined by the Investigator (Phase II)

DOR is defined as the time from the first occurrence of a documented objective response to disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).

Time frame:
Up to approximately 50 months
Reported as:
Median · Months
Duration of Response (DOR) as Determined by the Investigator (Phase II)
MonthsGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Duration of Response (DOR) as Determined by the Investigator (Phase II)NA (0 to 28)NA (0 to 28)NA (1 to 27)
SecondaryProgression-free Survival (PFS) as Determined by the Investigator (Phase II)

PFS is defined as the time from randomization to the first occurrence of disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The earliest contributing event to PFS is reported. The range (min-max) values are based on censored observations (participants without a baseline-evaluable tumor assessment were censored at the date of randomization or first study treatment, plus 1 day).

Time frame:
Up to approximately 50 months
Reported as:
Median · Months
Progression-free Survival (PFS) as Determined by the Investigator (Phase II)
MonthsGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Progression-free Survival (PFS) as Determined by the Investigator (Phase II)NA (0 to 31)NA (0 to 30)NA (3 to 30)
SecondaryPFS at 1 Year as Determined by the Investigator (Phase II)

PFS at 1 year is defined as the proportion of participants with disease progression or relapse as determined by the investigator, or death from any cause within 1 year of randomization.

Time frame:
1 year
Reported as:
Number · Percentage of participants
PFS at 1 Year as Determined by the Investigator (Phase II)
Percentage of participantsGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
PFS at 1 Year as Determined by the Investigator (Phase II)77.47 (63.65 to 91.29)70.83 (55.59 to 86.07)81.82 (65.70 to 97.94)
SecondaryEvent-free Survival (EFS) as Determined by the Investigator (Phase II)

EFS is defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, initiation of new anti-lymphoma therapy (NALT), or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).

Time frame:
Up to 50 months
Reported as:
Median · Months
Event-free Survival (EFS) as Determined by the Investigator (Phase II)
MonthsGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Event-free Survival (EFS) as Determined by the Investigator (Phase II)NA (2 to 31)NA (0 to 30)NA (3 to 30)
SecondaryTime to Deterioration in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale
Time frame:
C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)
Reported as:
Median · Months
Time to Deterioration in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale
MonthsArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Time to Deterioration in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) SubscaleNA (2.3 to NA)6.5 (2.1 to NA)
SecondaryTime to Deterioration in Physical Functioning and Fatigue as Measured by the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30)
Time frame:
C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)
Reported as:
Median · Months
Time to Deterioration in Physical Functioning and Fatigue as Measured by the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30)
MonthsArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Time to Deterioration in Physical Functioning and Fatigue as Measured by the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30)2.3 (1.2 to 5.4)2.3 (0.8 to NA)
SecondaryPolatuzumab Vedotin Serum Concentrations
Time frame:
C2D1, C6D1
Reported as:
Geometric mean · ug/mL
Polatuzumab Vedotin Serum Concentrations
ug/mLGroup B: Phase Ib Mosunetuzumab + CHP-PolaArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
C2D1 pre-dose0.993 ± 779.41.99 ± 80.71.73 ± 107.9
C6D1 pre-dose2.76 ± 820.18.13 ± 34.55.8 ± 42
SecondaryPolatuzumab Vedotin Antibody-conjugated Monomethyl Auristatin E (acMMAE) Serum Concentrations
Time frame:
C1D1-C6D1
Reported as:
Geometric mean · ng/mL
Polatuzumab Vedotin Antibody-conjugated Monomethyl Auristatin E (acMMAE) Serum Concentrations
ng/mLGroup B: Phase Ib Mosunetuzumab + CHP-PolaArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
C1D1 post-dose620 ± 54.5668 ± 21.2584 ± 23.1
C1D2 pre-dose219 ± 412.2——
C1D2 24hrs post-dose115 ± 658.3275 ± 28.2—
C1D8 pre-dose23 ± 1040.442 ± 82—
C1D15 pre-dose8.22 ± 550.413.2 ± 87.4—
C2D1 pre-dose4.87 ± 6266.81 ± 80.17.09 ± 95.5
C2D1 post-dose656 ± 21.1653 ± 18654 ± 21
C3D1 pre-dose19.2 ± 58.715.8 ± 39.5—
C3D1 post-dose144 ± 112947.3544 ± 90.7—
C4D1 pre-dose16.8 ± 79.616.8 ± 50.315.6 ± 41.4
C4D1 post-dose783 ± 26.5614 ± 15.4696 ± 24.1
C5D1 pre-dose7.14 ± 343.519 ± 39.7—
C5D1 post-dose544 ± 37.6605 ± 21.6—
C6D1 pre-dose11.8 ± 476.621.2 ± 34.717.3 ± 40.8
SecondaryPolatuzumab Vedotin Unconjugated Mono-methyl Auristatin E (MMAE) Serum Concentrations
Time frame:
C1D1-C6D1
Reported as:
Geometric mean · ng/mL
Polatuzumab Vedotin Unconjugated Mono-methyl Auristatin E (MMAE) Serum Concentrations
ng/mLGroup B: Phase Ib Mosunetuzumab + CHP-PolaArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
C1D1 post-dose0.535 ± 464.60.55 ± 71.10.432 ± 78.8
C1D2 pre-dose1.94 ± 114.2——
C1D2 24hrs post-dose3.3 ± 97.82.82 ± 51.9—
C1D8 pre-dose2.95 ± 80.91.27 ± 93.6—
C1D15 pre-dose0.604 ± 113.30.301 ± 104.1—
C2D1 pre-dose0.187 ± 47.30.0773 ± 110.20.0697 ± 87
C2D1 post-dose0.238 ± 640.137 ± 840.116 ± 56.3
C3D1 pre-dose0.168 ± 920.146 ± 96.9—
C3D1 post-dose0.111 ± 173.90.203 ± 92.7—
C4D1 pre-dose0.0491 ± NA0.14 ± 93.80.106 ± 88.9
C4D1 post-dose0.0825 ± 188.30.186 ± 66.10.164 ± 43.6
C5D1 pre-dose0.0741 ± 2470.137 ± 74.4—
C5D1 post-dose0.212 ± 54.20.17 ± 38.1—
C6D1 pre-dose0.0967 ± 194.20.142 ± 63.80.0974 ± 82.4
SecondaryMosunetuzumab Serum Concentrations
Time frame:
C1D1-C5D1
Reported as:
Geometric mean · ug/mL
Mosunetuzumab Serum Concentrations
ug/mLGroup A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)
C1D1 post-dose0.157 ± 22.10.181 ± 26.7—0.155 ± 34.10.132 ± 73.2
C1D1 2 hrs post-dose0.152 ± 27.80.163 ± 25.8—0.151 ± 28.1—
C1D2 2 hrs post-dose——0.145 ± 80——
C1D2 24 hrs post-dose0.103 ± 23.30.112 ± 8.10.0947 ± 60.20.096 ± 35.70.0825 ± 46.1
C1D8 pre-dose0.0331 ± 490.0218 ± 153.20.0334 ± 113.60.0253 ± 62.20.0263 ± 77
C1D8 post-dose0.342 ± 18.80.427 ± 36.20.354 ± 36.90.426 ± 30.30.376 ± 38.8
C1D8 2hrs post-dose0.32 ± 28.50.409 ± 50.10.349 ± 43.10.388 ± 27.6—
C1D15 pre-dose0.0866 ± 47.90.0884 ± 52.80.0911 ± 57.70.0953 ± 41.80.102 ± 47.7
C1D15 post-dose2.83 ± 22.65.71 ± 38.65.72 ± 447.13 ± 27.76.31 ± 34.8
C1D15 2 hrs post-dose2.28 ± 7.55.66 ± 38.75.92 ± 18.56.56 ± 28.4—
C2D1 pre-dose0.549 ± 24.31.52 ± 49.4—1.67 ± 32.11.46 ± 62.8
C2D1 post-dose2.86 ± 7.26.75 ± 42.2—8.31 ± 27.47.69 ± 38.3
C2D1 2 hrs post-dose2.38 ± 1.27.33 ± 44.77.65 ± 35.18.28 ± 26.7—
C2D2 pre-dose——1.37 ± 38.6——
C2D2 post-dose——8.9 ± 34.1——
C3D1 pre-dose0.458 ± 36.31.08 ± 53.31.21 ± 45.11.11 ± 30.20.885 ± 43
C3D1 post-dose3.37 ± 23.47.19 ± 30.86.66 ± 41.37.3 ± 39.26.76 ± 28.9
C4D1 pre-dose0.502 ± 36.91.09 ± 44.40.782 ± 901.03 ± 33.90.932 ± 52
C4D1 post-dose3.24 ± 31.37.38 ± 26.34.09 ± 837.41 ± 445.55 ± 80.3
C5D1 pre-dose0.426 ± 51.71.02 ± 620.33 ± 176.61.12 ± 31.60.935 ± 106.1
SecondaryBaseline Prevalence and Incidence of Treatment Emergent Anti-drug Antibodies (ADA) to Mosunetuzumab

Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).

Time frame:
Cycles 1, 2, 6, 16, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)
Reported as:
Number · Number of participants
Baseline Prevalence and Incidence of Treatment Emergent Anti-drug Antibodies (ADA) to Mosunetuzumab
Number of participantsGroup A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)
Positive sample at baseline00000
Not positive at baseline3483833
Positive for treatment-emergent ADA00000
Positive for treatment-induced ADA00000
Positive for treatment-enhanced ADA00000
Negative for treatment-emergent ADA3463937
SecondaryBaseline Prevalence and Incidence of Treatment Emergent ADA to Polatuzumab Vedotin

Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).

Time frame:
Cycles 1, 2, 6, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)
Reported as:
Number · Number of participants
Baseline Prevalence and Incidence of Treatment Emergent ADA to Polatuzumab Vedotin
Number of participantsGroup B: Phase Ib Mosunetuzumab + CHP-PolaArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Positive sample at baseline012
Not positive at baseline83219
Positive for treatment-emergent ADA001
Positive for treatment-induced ADA001
Positive for treatment-enhanced ADA000
Negative for treatment-emergent ADA63720

Adverse events

Collected over Up to approximately 30 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A1: Phase Ib Mosunetuzumab + CHOP2/3 (66.7%)3/3 (100%)3/3 (100%)
Group A2: Phase Ib Mosunetuzumab + CHOP1/4 (25%)4/4 (100%)4/4 (100%)
Group B: Phase Ib Mosunetuzumab + CHP-Pola6/8 (75%)6/8 (75%)8/8 (100%)
Group C: Phase II Mosunetuzumab + CHOP9/40 (22.5%)20/40 (50%)40/40 (100%)
Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)5/40 (12.5%)24/38 (63.2%)38/38 (100%)
Arm 2: Phase II Rituximab + CHP-Pola (Randomized)3/22 (13.6%)3/22 (13.6%)22/22 (100%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventGroup A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
Febrile neutropeniaBlood and lymphatic system disorders0/32/40/86/405/381/22
Supraventricular tachycardiaCardiac disorders1/30/40/80/400/380/22
Pneumocystis jirovecii pneumoniaInfections and infestations1/30/40/80/400/380/22
SepsisInfections and infestations1/31/40/80/400/380/22
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/40/81/400/380/22
HypotensionVascular disorders1/30/40/80/400/380/22
AnaemiaBlood and lymphatic system disorders0/30/42/81/402/380/22
Cytokine release syndromeImmune system disorders0/31/40/80/405/380/22
COVID-19Infections and infestations0/30/42/80/401/380/22
PneumoniaInfections and infestations0/31/40/83/400/380/22
Most frequent other events
Showing 10 of 178
Most frequent other events
EventGroup A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)
NauseaGastrointestinal disorders1/31/46/822/4017/389/22
AnaemiaBlood and lymphatic system disorders2/32/42/817/409/385/22
ThrombocytopeniaBlood and lymphatic system disorders2/31/43/85/406/381/22
DiarrhoeaGastrointestinal disorders2/31/42/812/4012/384/22
Oedema peripheralGeneral disorders2/32/42/88/405/380/22
FallInjury, poisoning and procedural complications2/30/42/80/400/380/22
Platelet count decreasedInvestigations2/31/41/85/404/383/22
Decreased appetiteMetabolism and nutrition disorders2/32/44/815/4011/381/22
HypomagnesaemiaMetabolism and nutrition disorders2/31/45/86/404/380/22
Neuropathy peripheralNervous system disorders2/30/40/813/403/384/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)Total
Mean72.0 ± 13.071.3 ± 3.460.1 ± 18.063.4 ± 11.065.0 ± 10.057.7 ± 14.363.2 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Group A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)Total
Female0131814844
Male33522261473
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)Total
Hispanic or Latino01332312
Not Hispanic or Latino335363518100
Unknown or Not Reported0001315
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A1: Phase Ib Mosunetuzumab + CHOPGroup A2: Phase Ib Mosunetuzumab + CHOPGroup B: Phase Ib Mosunetuzumab + CHP-PolaGroup C: Phase II Mosunetuzumab + CHOPArm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized)Arm 2: Phase II Rituximab + CHP-Pola (Randomized)Total
American Indian or Alaska Native0000101
Asian000105015
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000011
White34828302093
More than one race0000000
Unknown or Not Reported0002417
08

Study locations

41 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35233, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • University of California; Moores Cancer Center
    La Jolla, California 92093, United States
  • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica
    Santa Monica, California 90404-2023, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903-4923, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Scott and White Hospital; Cancer Center
    Temple, Texas 76508, United States
  • Medical College of Wisconsin, Inc.
    Milwaukee, Wisconsin 53226-3596, United States
  • Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU
    Salzburg, 5020, Austria
  • LKH Steyr
    Steyr, 4400, Austria
  • Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien
    Wien, 1090, Austria
  • Hanusch-Krankenhaus
    Wien, 1140, Austria
  • CHU Henri Mondor; Service d'Oncologie Medicale
    Creteil, 94010, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Hôpital Saint-Louis
    Paris, 75475, France
  • Centre Henri Becquerel- Centre de Lutte Contre le Cancer
    Saint Herblain, 44805, France
  • Gustave Roussy
    Villejuif, 94805, France
  • Pusan National University Yangsan Hospital
    Gyeongsangnam-do, 50612, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Maria Sklodowska-Curie Memorial Cancer Centre
    Gliwice, 44-102, Poland
  • Ma?opolskie Centrum Medyczne
    Kraków, 30-501, Poland
  • Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka
    Slupsk, 76-200, Poland
  • Instytut Hematologii i Transfuzjologii; Klinika Zaburze? Hemostazy i Chorób Wewn?trznych
    Warsaw, 02-776, Poland
  • Katedra i Klinika Hematologii; Nowotworów Krwi i Transplantacji Szpiku
    Wroc?aw, Poland
  • Institut Catala d?Oncologia Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Sevilla 41071, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 8041, Spain
  • Hospital San Pedro de Alcantara; Servicio de Hematología
    Caceres, 10003, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2023, 55 months.

Results were first posted in Dec 2024, 1 year 2 months after primary completion.

Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's 55 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Sep 19, 2018
StartActual
Mar 8, 2019
Primary completionActual
Oct 12, 2023
CompletionActual
Oct 12, 2023
Results first posted
Dec 18, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03677141
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
Mar 8, 2019
Primary completion
Oct 12, 2023
Completion
Oct 12, 2023
Results posted
Dec 18, 2024
Last update
Dec 18, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mosunetuzumab · Polatuzumab vedotin

Start the discussion